Correction to: Antibiotics in the pipeline: a literature review (2017–2020)

Correction to: Infection 10.1007/s15010-021-01709-3

On page 6 following the heading “Omadacycline”, the following items need clarification:

• In the 2nd paragraph, comparing omadacycline (n = 388 patients) and moxifloxacin (n = 386 patients).

• In the 2nd paragraph, the rates of adverse events given are those that corresponded to treatment discontinuation due to an adverse event.

• In the 3rd paragraph, omadacycline had been tested in 316 patients, compared to linezolid in 311 patients.

• In the 3rd paragraph, in the MITT, the early response rate was 84.8% vs. 85.5%, respectively.

• In the 3rd paragraph, the rates of adverse events given are those that were considered treatment-related.

Table 1 (table updated),

• omadacycline does not have EMA approval (indicated by an ‘X’).

• omadacycline has activity against ESBL (indicated by a check mark) (Table 1).

Table 1.

Summary of antibiotics in the pipeline and their spectrum of activities

	Name	FDA approved	EMA Approved	Antibiotic class	Indication/usage	CRAB	CRPA	CRE	KPC	MRSA	VRE	ESBL
2017
1.	Delafloxacin	✓	✓	Fluoroquinolone	ABSSSI	X	X	X	X	✓	X	X
2.	Meropenem/vaborbactam	✓	✓	Carbapenem/β-lactamases inhibitor	cUTI; cIAI	X	X	X	✓	X	X	X
2018
1.	Plazomicin	✓	✓	Aminoglycoside	cUTI	X	X	✓	X	✓	X	✓
2.	Eravacycline	✓	✓	Tetracycline	cIAI	✓	X	X	X	✓	✓	✓
3.	Omadacycline	✓	X	Tetracycline	CAP; ABSSSI		X	X	X	✓	✓	✓
2019
1.	Lefamulina	X	X	Pleuromutilin	CABP	X	X	X	X	✓	✓	X
2.	Cefiderocol	✓	✓	Cephalosporin	cUTI, HAP/VAP, bloodstream infection, and sepsis	✓	✓	✓	✓	X	X	✓
3.	Pretomanid	✓	✓	Nitroimidazooxazine	XDR-TB; MDR-TB
2020
1.	Levonadifloxacin(EMROK)/alalevonadifloxacin; (approved by DCGI for use in India)	X	X	Fluoroquinolone	ABSSSI					✓
2.	Iclaprima	X	Withdrawn	DHFR inhibitors	ABSSSI	X	X	X	X	✓	X	X
3.	Imipenem/cilastatin + relebactam	✓		Carbapenem/β-lactamases inhibitor	cUTI, AP, cIAI, HAP, VAP	X	✓ Except MBL Producer	✓	✓	X
Phase III trial
1.	Solithromycin	(Phase III)		4th Generation macrolide	CAP	X	X	X	X	X	X	X
2.	Sulopenem	(Phase III)		Thiopenem b-lactam	UTI; cIAI	X	X	X	X	X	X	✓
3.	Cefilavacin	(Phase III)		Glycopeptide-β-lactam (Cephalosporin) hybrid	ABSSSI	X	X	X	X	✓	✓	X
4.	Cefepime + AAI101	(Phase III)		4th generation cephalosporin/β-lactamases inhibitor	cUTI	X	X	✓	X	X	X	✓
5.	Ridinilazole	(Phase III)		Inhibition of cell division, inhibition of toxin production	CDI	X	X	X	X	X	X	X
6.	Gepotidacin	(Phase III)		Triazaacenaphthylene	ABSSSI; Uncomplicated urogenital gonorrhea	X	X	X	X	✓	X	X
7.	Sulbactam/diazabicyclooctane	(Phase III)		β-Lactam/β-lactamases inhibitor	cUTI	✓	X	✓	X	X	X	✓
8.	Zoliflodacin	(Phase III)		Spiropyrimidinetrione	Uncomplicated gonorrhea	X	X	X	X	X	X	X
9.	Taniborbactam	(Phase III)		β-Lactam/β-lactamases inhibitor	cUTI	X		✓
11.	Contezolid	(Phase III in china whereas phase II in USA)		Oxazolidinone	ABSSSI					✓

CRAB, carbapenem-resistant Acinetobacter baumannii; CRPA, carbapenem-resistant Pseudomonas aeruginosa; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococcus; ESBL, extended-spectrum beta-lactamases; ABSSSI, acute bacterial skin and skin structure infections; cUTI, complicated urinary-tract infections; cIAI, complicated intra-abdominal infections; CAP, community-acquired pneumonia; CABP, community-acquired bacterial pneumonia; HAP/VAP, hospital-acquired pneumonia (nosocomial pneumonia) and ventilator-associated pneumonia; XDR-TB, extensively drug-resistant tuberculosis; MDR-TB, multi-drug-resistant tuberculosis; CDI, Clostridium difficile infection

^aNew drug application (NDA)

The original article has been corrected.